Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia.

Haematologica - 1 Feb 2019

Ok Chi Young, Loghavi Sanam, Sui Dawen, Wei Peng, Kanagal-Shamanna Rashmi, Yin C Cameron, Zuo Zhuang, Routbort Mark J, Tang Guilin, Tang Zhenya, Jorgensen Jeffrey L, Luthra Rajyalakshmi, Ravandi Farhad, Kantarjian Hagop M, DiNardo Courtney D, Medeiros L Jeffrey, Wang Sa A, Patel Keyur P

Abstract excerpt

Persistence of IDH1 or IDH2 mutations in remission bone marrow specimens of patients with acute myeloid leukemia has been observed, but the clinical impact of these mutations is not well known. In this study, we evaluated 80 acute myeloid leukemia patients with known IDH1 R132 or IDH2 R140/R172 mutations and assessed their bone marrow at the time of remission to determine the potential impact of persistent IDH1/2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to fms-Like Tyrosine Kinase 3
Share to High-Throughput Nucleotide Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunophenotyping

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Nucleophosmin

Share to Recurrence

Share to Remission Induction

Source

Open in PubMed Open full text

Identifiers

PMID: 30171025
DOI: 10.3324/haematol.2018.191148
PMCID: PMC6355476

Genes

IDH1
IDH2
FLT3
NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia.PMID 30171025Read ↗

Acquisition of IDH2 mutations in relapsed/refractory AML is associated with worse patient outcomes.Semantic proximity Read ↗

Utility of IDH1/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemiaSemantic proximity Read ↗

Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia.Semantic proximity Read ↗

Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation.Semantic proximity Read ↗

The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AMLSemantic proximity Read ↗

Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia.Semantic proximity Read ↗

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.Semantic proximity Read ↗

Disease characteristics and monitoring of IDH1/IDH2-mutated acute myeloid leukemiaSemantic proximity Read ↗

Persistent<i>IDH</i>mutations are not associated with increased relapse or death in patients with<i>IDH</i>-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamideSemantic proximity Read ↗

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.Semantic proximity Read ↗

Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapseSemantic proximity Read ↗

Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.